8-K: Telesis Bio to Voluntarily Delist from Nasdaq Amid Compliance Issues

Telesis Bio has announced its decision to delist from the Nasdaq Global Select Market due to its inability to meet minimum listing requirements.

Summary

• Telesis Bio has decided to voluntarily delist its common stock from the Nasdaq Global Select Market.
• The company intends to file a Form 25 with the SEC around September 20, 2024, to remove its stock from the Nasdaq.
• The last trading day for Telesis Bio's stock on Nasdaq is expected to be around September 30, 2024.
• This decision was made after the company failed to meet Nasdaq's minimum stockholders' equity requirement of $10 million and the minimum market value of publicly held shares requirement of $5 million.
• Telesis Bio will continue to be subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act.
• The company anticipates its stock will be quoted on an over-the-counter market operated by OTC Markets Group Inc. after delisting.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's failure to meet listing requirements and the subsequent delisting from Nasdaq, which is generally viewed as a negative event for investors.

Positives

• The company expects its stock to be quoted on an over-the-counter market, allowing for continued trading.

Negatives

• Telesis Bio failed to meet Nasdaq's minimum stockholders' equity requirement of $10 million.
• The company also failed to meet the minimum market value of publicly held shares requirement of $5 million.
• The delisting will remove the company from the Nasdaq Global Select Market.

Risks

• There is no guarantee that a broker will continue to make a market in the company's stock on the OTC market.
• Trading of the stock may not continue on an OTC market or otherwise.
• The company's inability to meet Nasdaq's listing requirements raises concerns about its financial health.

Future Outlook

Telesis Bio expects its stock to be quoted on an over-the-counter market after delisting, but there is no guarantee of continued trading or market making.

Management Comments

• The board of directors determined that delisting is in the best interests of the company and its stockholders.
• The significant costs and regulatory compliance burden of remaining a Nasdaq-listed company were impairing the company's ability to execute on its business plan and to generate value for its stockholders.

Industry Context

This delisting highlights the challenges faced by smaller biotech companies in maintaining compliance with exchange listing requirements, especially when facing financial difficulties.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain the minimum listing requirements of major exchanges like Nasdaq.
• Companies like Athersys and Ocugen have also faced similar challenges with maintaining listing compliance.
• The delisting of Telesis Bio is not uncommon in the biotech sector, where companies often face financial pressures and regulatory hurdles.

Stakeholder Impact

• Shareholders may experience reduced liquidity and potentially lower valuations due to the delisting.
• Employees may face uncertainty about the company's future prospects.
• Customers and suppliers may be concerned about the company's financial stability.

Next Steps

• Telesis Bio will file a Form 25 with the SEC around September 20, 2024.
• The company expects its stock to be quoted on an over-the-counter market after delisting.

Key Dates

Keywords

Delisting, Nasdaq, OTC, Stockholders' Equity, Market Value, Compliance, TBIO, Telesis Bio